Soluplus®, Eudragit®, HPMC-AS foams and solid dispersions for enhancement of Carvedilol (cas 72956-09-3) dissolution rate prepared by a supercritical CO2 process
-
Add time:07/16/2019 Source:sciencedirect.com
The present work is aimed towards designing advanced materials by means of sustainable processes. In that sense, the utilization of supercritical CO2 (scCO2) for processing of pharmaceutical polymers (Soluplus®, Eudragit®, and hydroxypropyl methylcellulose acetate succinate), alone and with an addition of cardiovascular drug Carvedilol (cas 72956-09-3), was explored. Employed single-step static scCO2 process (pressure of 30 MPa and temperature of 100 °C for 2 h) enabled fabrication of solvent-free polymeric foams and Carvedilol solid dispersions with controlled microstructure and average pore diameter of 101–257 μm suitable for application in the pharmaceutical industry. ScCO2 did not remain in the foams after processing or affected the polymer composition, while Carvedilol formed hydrogen bonds with the polymers. Carvedilol was molecularly dispersed in the fabricated solid dispersions and its transition from the crystalline to amorphous form was complete. Korsmeyer-Peppas model was successfully used for the mathematical description of Carvedilol dissolution from solid dispersions. The dissolution rate of Carvedilol in acidic medium was significantly enhanced by its dispersion in tested polymers using the proposed high-pressure method.
We also recommend Trading Suppliers and Manufacturers of Carvedilol (cas 72956-09-3). Pls Click Website Link as below: cas 72956-09-3 suppliers
Prev:The cardioprotective effects of Carvedilol (cas 72956-09-3) on ischemia and reperfusion injury by AMPK signaling pathway
Next:Comparative study of Carvedilol (cas 72956-09-3) and quinidine for inhibiting hKv4.3 channel stably expressed in HEK 293 cells) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Enhancement of oral bioavailability of poorly water soluble Carvedilol (cas 72956-09-3) by chitosan nanoparticles: Optimization and pharmacokinetic study07/22/2019
- Solidification of Carvedilol (cas 72956-09-3) loaded SMEDDS by swirling fluidized bed pellet coating07/20/2019
- Prophylactic use of Carvedilol (cas 72956-09-3) to prevent ventricular dysfunction in patients with cancer treated with doxorubicin07/21/2019
- Carvedilol (cas 72956-09-3) attenuates experimentally induced silicosis in rats via modulation of P-AKT/mTOR/TGFβ1 signaling07/19/2019
- Carvedilol (cas 72956-09-3) and thyroid hormones co-administration mitigates oxidative stress and improves cardiac function after acute myocardial infarction07/18/2019
- Comparative study of Carvedilol (cas 72956-09-3) and quinidine for inhibiting hKv4.3 channel stably expressed in HEK 293 cells07/17/2019
- The cardioprotective effects of Carvedilol (cas 72956-09-3) on ischemia and reperfusion injury by AMPK signaling pathway07/15/2019
- Carvedilol (cas 72956-09-3) blockage of delayed rectifier Kv2.1 channels and its molecular basis07/14/2019
- The adrenergic receptor antagonist Carvedilol (cas 72956-09-3) interacts with serotonin 2A receptors both in vitro and in vivo07/13/2019
-
Health and Chemical more >
-
Related Products